Lifetime suicide rates in treated schizophrenia: 1875–1924 and 1994–1998 cohorts compared

Healy, David; Harris, M. L.; Tranter, Richard; Gutting, P.; Austin, Regina; Jones-Edwards, G.; Roberts, Anthony

doi:10.1192/bjp.188.3.223

Cited by 48 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…for those needing depot preparations. 1,28 In line with these findings, the presence of akathisia, as well as parkinsonism, was associated with an increased risk of suicide among the subjects interviewed.…”

Section: Discussionsupporting

confidence: 67%

Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy

Lippi¹,

Smit

Jordaan

et al. 2009

S. Afr. J. Psych.

View full text Add to dashboard Cite

In this paper we report on the current suicide risk in the study cohort and its association with the following factors: (i) the course of depressive and psychotic symptomatology; (ii) psychiatric pharmacotherapy -adverse effects of and compliance with pharmacotherapy and its influence on symptomatology; and (iii) the effect of cannabis abuse and insight into illness. MethodThe previous paper described the details of the methodology of this study. Department of Psychiatry, University of Pretoria and Weskoppies HospitalObjective. This study followed up, after a period of 20 years, a group of patients with schizophrenia who were considered to be at high risk for suicide. In Part 1 we reported on outcome and associated social factors, and in this paper we discuss re-evaluated suicide risk in these patients and investigate symptomatology and pharmacotherapy over the past two decades.Method. The subjects were interviewed and a questionnaire evaluating suicide risk was completed. The Beck Hopelessness Scale (BHS) was administered and ratings were compared with those from the original study. The Calgary Depression Scale for Schizophrenia (CDSS) was also administered. Crosstabulations were then performed to identify factors associated with increased suicide risk. For those subjects who had committed suicide since the original study, a psychological autopsy was performed. Despite current knowledge about this subject, suicide remains notoriously and ominously unpredictable in patients with schizophrenia.

show abstract

Section: Discussionsupporting

confidence: 67%

Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy

Lippi¹,

Smit

Jordaan

et al. 2009

S. Afr. J. Psych.

View full text Add to dashboard Cite

show abstract

“…42 The mortality rates where the death certificate mentioned schizophrenia were 8.2 per million for men and 7.1 per million for women. 20 65-74 14 suicide rate in psychotic patients 43 and the lifetime suicide attempt rate is around 22%. 11 A review of the literature between 1939 and 1998 estimated that the 20-year suicide rate in schizophrenia is between 14 and 22%.…”

Section: Mortality From Psychosismentioning

confidence: 99%

Structural neuroimaging in psychosis: a systematic review and economic evaluation

Albon¹,

Tsourapas²,

Frew³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

“…A recent study in Wales has shown that current rates of suicide among those with schizophrenia and other psychoses appear to be twentyfold higher than they were in the period 1875 to 1924. 22 Where the average life expectancy of the general population of the United States is 76 years (72 years for men and 80 years for women), the corresponding figure for the population with schizophrenia is 61 years (57 years for men and 65 years for women). In other words, compared with the general population, patients with schizophrenia have a 20% reduced life expectancy.…”

Section: Mortalitymentioning

confidence: 99%

An Outcome Measure in Schizophrenia: Mortality

Seeman

2007

Can J Psychiatry

View full text Add to dashboard Cite

Objective: To determine the current outcome of schizophrenia, with mortality rate as the outcome measure. Method: Recent health, suicide, victim of violence, and mortality statistics were reviewed. Results: The general health of individuals with schizophrenia suffers from neglect, poor life style choices, and current treatments that increase death rates. Conclusion: Mortality in schizophrenia is rising, and it is the responsibility of physicians and health care planners to intervene.

show abstract

Lifetime suicide rates in treated schizophrenia: 1875–1924 and 1994–1998 cohorts compared

Abstract: These findings point to an increase in suicide rates for patients with schizophrenia.

Cited by 48 publications

References 21 publications

Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy

Suicide Risk in Schizophrenia - a follow-up study after 20 years. Part 2: Symptomatology and pharmacotherapy

Structural neuroimaging in psychosis: a systematic review and economic evaluation

An Outcome Measure in Schizophrenia: Mortality

Contact Info

Product

Resources

About